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The human diploid genome has approximately 40,000 functioning conserved genes dis-
tributed within 6 billion base pairs of DNA. Most individuals carry a few heterozygous
deleterious mutations and this leads to an increased risk of recessive disease in the off-
spring of cousin unions. Rare recessive disease is more common in the children of cousin
marriages than in the general population, even though <1% of marriages in the Western
World are between first cousins. But more than 90% of the children of cousin marriages do
not have recessive disease and are as healthy as the rest of the population. A mathematical
model based on these observations generates simultaneous equations linking the mean
number of deleterious mutations in the genome of adults (M ), the mean number of new
deleterious mutations arising in gametogenesis and passed to the next generation (N ) and
the number of genes in the human diploid genome (L). The best estimates are that M is
<7 and N is approximately 1. The nature of meiosis indicates that deleterious mutations
in zygotes will have a Poisson distribution with a mean of M+N. There must be strong
selective pressure against zygotes at the upper end of the Poisson distribution otherwise
the value of M would rise with each generation. It is suggested that this selection is based
on synergistic interaction of heterozygous deleterious mutations acting in large complex
highly redundant and robust genetic networks.To maintain the value of M in single figures
over many thousands of generations means that the zygote loss must be of the order of
30%. Most of this loss will occur soon after conception but some will occur later; during
fetal development, in infancy and even in childhood. Selection means genetic death and
this is caused by disease to which the deleterious mutations predispose. In view of this
genome sequencing should be undertaken in all infant deaths in which the cause of death
is not ascertained by standard techniques.
Keywords:whole genome sequencing, deleteriousmutations, sudden unexpected death in infancy, bacterial toxins,
proteomics, molecular autopsy
INTRODUCTION
Infant mortality rates have fallen progressively in UK in the last
50 years, from 18 infant deaths per 1000 live births in 1970 to
4/1000 in 2012 (1). The majority of infant deaths occur in the
first month of life (70% in England and Wales in 2012). The post-
neonatal mortality rate (infant deaths between 1 and 12 months of
age) has also fallen from over 5/1000 live births in 1970 to 1.2/1000
in 2012. The majority of infant deaths after the first month of life
are due to sudden unexpected death in infancy (SUDI). The fre-
quency of this condition fell markedly between 1988 and 1995
coinciding with a move from prone to supine sleeping. This fol-
lowed epidemiological studies, which identified the risk of the
prone sleeping position in the early months of life (2, 3). It is one
of epidemiology’s great triumphs. The number of infant deaths
that remain unexplained after a detailed autopsy has, however,
leveled off in recent years and there are still approximately 300
such infant deaths (0.5/1000) each year in England and Wales.
Sudden unexpected death in infancy is more common in infants
with young single mothers, or mothers with partners who are
unemployed (4). The parents commonly smoke and there is an
increased incidence of drug abuse. The infants are less likely to have
been breast fed and the parents are less likely to follow national
guidelines on safe sleeping practice. SUDI is a condition associ-
ated with poor social circumstances and if those conditions could
be improved the number of cases would undoubtedly fall. Indeed,
the number of cases would fall if all that happened was parents
stopped smoking. But it is naïve to believe that the condition could
be eliminated in this way. Furthermore, emphasis on poor parent-
ing is of no comfort to those mothers whose infants died in spite
of exemplary care and there are many such cases.
In my opinion, the infant autopsy in the twenty-first century
should be improved. It should include genome sequencing and
analysis of body fluids for bacterial secretory products as well as
the standard dissection and histological examination of tissue.
This is the molecular autopsy to supplement the standard autopsy.
The current methods for assessing infection are inadequate and
there is plenty of evidence to indicate that analysis of the genome
will provide valuable information in many cases (5). Parents have
a right to know why their infant died, and pathologists have a duty
to do all that they can to answer that question. Lecturing parents
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on their inadequacy is no substitute for a full scientific assessment
of the cause of death.
In this article, I make a case for the use of whole genome or
whole exome sequencing in the infant autopsy. Initially, it will be
used for cases where death is unascertained after a detailed stan-
dard autopsy. It should also be used in cases of childhood death
when the cause is unclear. But eventually, it will be used in all infant
deaths because the information supplied will be of considerable
value in the broader understanding of the function of human genes
as well as for genetic counseling. Genome sequencing should be
mandatory in cases of infant death attributed to the shaken baby
syndrome, because the evidence for trauma is often weak and some
of these cases could be due to natural disease (6). Avoiding a single
prosecution will save many multiplies of the $2000 estimated cost
of whole genome sequencing.
NEUTRAL MUTATIONS
If two homologous strands of DNA from an autosomal chro-
mosome from the same person or from a different person are
compared over 99% of the bases will be exactly the same (7). The
same will apply to the X chromosome and to the Y chromosome
when they are compared between individuals. However, discrep-
ancies do occur in approximately 1 in 300 bases and these base
changes are due to mutations in previous generations. The rate
of mutation when DNA is copied in mitosis is of the order of
5× 10−10 bp per mitotic division (8). The number of bases in the
diploid genome is 6× 109; thus, approximately three bases will
be miscopied each time a cell divides. There are over 40 divisions
between the zygote and the oocyte, and over 60 between the zygote
and spermatozoa. Thus, each individual will have over 100 base
changes due to mutations occurring in parental gametogenesis.
These are private mutations, they are unlikely to be present in any
other member of the human race and they are not shared with
siblings.
An individual will also inherit over 100 mutations that arose
during grand-parental gametogenesis. These are also private
mutations, but they will be present in the genome of parents and
will be shared with siblings. Another 100 mutations will have arisen
in the gametogenesis of great grandparents, and a further 100 from
mutagenesis in great great grandparents, and so on back through
thousands of generations. Obviously, grandparents produce twice
as many mutations as parents because there are four grandparents
and only two parents. But only half of the mutations are passed
on in each generation so the number of mutations acquired per
individual remains the same at over 100 for each generation.
If the current human variation is 1 in 300 bases and 100 new
mutations arise per generation then the process has been going on
for 100,000 generations or approximately 2.5 million years. Only
1–4% of the human genome is conserved; this is the protein cod-
ing and regulatory part of the genome (7). Thus, the majority of
base changes are neutral in evolutionary terms and there is no
selection against these mutations. But let us now consider the fate
of a new neutral mutation entering the genome of an individual.
If that individual has two children then there is a 25% chance
that the mutation is not present in the genome of either child; a
25% chance that it is present in the genome of both children and
a 50% chance that one child has a copy and the other does not.
A similar stochastic process occurs in subsequent generations and
the result is that most new neutral mutations are lost purely by
chance but a few increase in number from generation to gener-
ation, again purely by chance. Fisher was able to show that in a
stable population the chance of a new neutral mutation surviving
for n generations is 2/n, when n is large. But the number of copies,
if it does survive, will be close to n/2.
Those neutral mutations that survive will gradually expand in
the population over many generations and some will eventually be
present in over 1% of the human race. These are the common sin-
gle nucleotide polymorphisms used in genome wide association
studies (GWAS). The majority of these have been in the human
genome for over 10,000 generations.
Mutations in protein coding genes and regulatory genes can
also be neutral. A base change in a protein coding gene that does
not alter the amino acid sequence of the protein is termed a syn-
onymous change. These are commonly neutral. A base change that
alters the amino acid sequence is likely to be deleterious but can
be neutral. In the latter situation, the new protein is different but
works as well as the wild type protein. Or it could be that the new
protein is advantageous in certain situations and disadvantageous
in others; but neutral overall. Equally, regulatory changes can cause
faster or slower and stronger or weaker responses. This, once again,
might be advantageous in certain situations and disadvantageous
in others. These neutral changes will have similar kinetics to the
neutral base changes in non-coding regions described above. The
main genetic differences between individuals and between races
are due to neutral mutations in protein coding and regulatory
genes.
There is some evidence that in certain situations the heterozy-
gote can have an advantage over the homozygote for a particular
locus (9). This applies in particular to the HLA system of genes.
These loci are highly polymorphic and it appears that the heterozy-
gote is better at dealing with infection and avoiding autoimmune
disease than the homozygote. Indeed, bacteria and viruses adapt
by evolution to their hosts and new neutral mutations can thwart
that adaptation, at least for a few generations. Bacteria adhere to
surface proteins on cells and the heterozygote will have fewer pro-
teins of any one type than the homozygote; this again could be
advantageous. In certain infections, a strong regulatory response
is required, while in others a weaker response might be advanta-
geous. The individual with both responses in their repertoire will
be at an advantage.
DELETERIOUS MUTATIONS
A deleterious mutation is one in which the protein product of a
gene is not produced, is produced, and does not function, or is
produced and interferes with normal function. Equally, mutations
in regulatory elements can be deleterious if the regulatory function
is impaired. These mutations can arise from single base changes or
more extensive insertions, deletions, or frame shifts. The majority
of base changes due to mutation in spermatogenesis and oogene-
sis lead to neutral mutations in the genome and the best available
estimates are that the mean number of new deleterious mutations
arising in each generation is between 0.5 and 1.5 (10).
Let us define M as the mean number of deleterious muta-
tions in the germ line of adults and N as the mean number of
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new deleterious mutations arising in gametogenesis and passed
on to the next generation. Thus, the mean number of deleterious
mutations in zygotes is M+N.
If first cousins marry, they have an increased risk of bearing
children with recessive disease. This reflects the presence of het-
erozygous deleterious mutations in their grandparents that have
been passed to both cousins and then appear in the homozygous
form in their children. This indicates that we all carry a few dele-
terious mutations and the value of M is >1. But over 90% of the
children of cousin marriages do not suffer from a recognizable
recessive disease and are as healthy as the rest of the popula-
tion. This indicates that M is a small number and is probably
<10 (10).
The nature of meiosis indicates that deleterious mutations will
be distributed at random during the formation of spermatozoa
and oocytes. Thus, there will be a Poisson distribution of delete-
rious mutations in zygotes (Figure 1) with a mean <10. A more
precise model of this process has been published and the best esti-
mates obtained were M= 4–8 and N= 0.5–1.5. These estimates
were based on the assumption that there are 30,000 genes in the
haploid set (10). The current estimate is closer to 20,000 and this
means the value of M will be proportionally smaller.
If one new deleterious mutation enters the genome per gen-
eration and the mean number of deleterious mutations in adults,
after many thousands of generations, is still in single figures, then
there must be strong selection against the deleterious mutations.
This will operate at the upper end of the Poisson distribution. The
zygotes that carry the most deleterious mutations will be the least
likely to survive and develop into infants and eventually adults.
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FIGURE 1 |The distribution of deleterious mutations in zygotes and in
adults, based on a previously published theoretical model (13). The
deleterious mutations interact synergistically to impair the performance of
complex genetic systems. Zygote loss will be mainly immediately post
conception. The mean number of deleterious mutations (M ) in UK at
present is probably less than shown in the figure. It would fall even further
if N fell due to improved social conditions.
The number of zygotes lost by this process is not inconsiderable.
The mean in zygotes is M+N, and the mean in adults is M. To
achieve this change, approximately 30% of the zygotes at the upper
end of the Poisson distribution will fail to develop (11–13).
The process envisaged, and previously described, is that het-
erozygous deleterious mutations interact synergistically to impair
the performance of large complex genetic systems during devel-
opment. The individual systems consist of hundreds or thousands
of genes. A model along the following lines can explain what is
observed (10–13).
A. Zygotes, which have four deleterious mutations in an essential
genetic system, will not survive. Most of the loss will occur
shortly after conception, but a few deaths might arise later in
pregnancy or even in early infant life.
B. Zygotes, which have three deleterious mutations in an essential
system, are likely to survive and be born alive. The system will
function adequately most of the time, but will be less robust
than normal, and will be at risk of malfunction in response
to environmental stress. These infants might die in infancy or
childhood due to infection.
C. Zygotes with two deleterious mutations in an essential system
are likely to survive. Their system will function adequately most
of the time and will only be seriously compromised by a major
environmental stress. These infants could also die in infancy
due to infection.
D. Zygotes with one deleterious mutation in an essential system
will survive and their system will be robust and will function
adequately. They are unlikely to die in infancy.
E. Zygotes with zero deleterious mutations have systems, which
work beautifully. They grow to be intelligent and healthy adults
and have all the luck.
GENDER DIFFERENCES
Males are more likely to die than females in every year from birth
to old age (9, 14). They are also more likely to die in utero. In
SUDI, there is a constant ratio of three male deaths for every two
female deaths (15). The main genetic difference between males
and females is that males have only one X chromosome, while
females have two. The X chromosome carries approximately 5%
of the genome and thus carries in the region of 1000 genes (7).
Every male is 1000 genes short of a full set – it explains a great deal.
Female cells,however, express the same number of genes as male
cells. This is because one of the X chromosomes in every female
cell is inactivated. This is a random process occurring in stem cells.
It means that every female is actually two slightly different genetic
individuals within one body – this also explains a lot.
Inbreeding depression is an intriguing phenomenon observed
in laboratory animals (16, 17). Brother sister mating through
many generations leads to genetic homogeneity. Heterogenous
changes are gradually lost and each genetic locus contains iden-
tical genetic material. These animals, however, are sickly. There
is impaired development in utero, increased rates of fetal death,
low-birth weight, increased infections in early life, and a short-
ened life-span. There are two possible mechanisms that explain
inbreeding depression, one is recessive disease and the other is loss
of heterozygous advantage.
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Table 1 |This table shows the relative risk of SUDI in males with a
deleterious mutation on X, assuming that the excess is caused by sex
linked recessive disease.
Relative risk of SUDI
in males with a deleterious
mutation on the X chromosome
% of males with a deleterious
mutation on the X chromosome
SUDI (%) CONTROLS (%)
3 50 25
6 40 10
11 37 5
If 25% of control males have a deleterious mutation on X then 50% of SUDI
males will carry a deleterious mutation on X and the relative risk of SUDI will
rise threefold. Relative risk is the risk of a male with a deleterious mutation on X
compared with a male without a deleterious mutation on X. If only 5% of control
males have a significant deleterious mutation on X then 37% of SUDI males will
have an X-linked mutation and the relative risk will rise 11-fold. The calculations
are shown in the Section “Appendix.”
1. Recessive disease: there is a selection against deleterious muta-
tions during the process of producing genetic homogeneity and
therefore inbred animals have a reduced number of deleterious
mutations. However, any deleterious mutations that survive
will be homozygous and therefore cause recessive disease.
2. Loss of heterozygous advantage: heterozygous loci confer
advantage in fighting infection as discussed above in the section
on neutral mutations.
The relevance of inbreeding depression to male death in infancy
is that males have the equivalent of inbreeding depression on 5%
of the genome. A deleterious mutation on X will cause a recessive
disease in males but not in females. In females, only 50% of the cells
will express the deleterious gene product. Females will still have
heterozygous advantage on X as they are capable of expressing
both genes, albeit in different cells.
The number of deleterious mutations on the X chromosome
will be approximately M ÷ 40, because the X chromosome has
5% of the genome and we are considering the diploid cell. In
fact, the number is probably less in males because some dele-
terious mutations on X will be lethal in the male. The figures
in (Table 1) are calculated by assuming that the increased male
deaths in SUDI are entirely due to X-linked deleterious muta-
tions. The increased risk of SUDI with a deleterious mutation on
X will be between 3- and 11-fold, if the assumption is correct. This
indicates the potential value of sequencing the X chromosome
in SUDI.
If X-linked recessive disease is not the explanation, or the sole
explanation, then the alternative is loss of heterozygous advan-
tage. This would point to infection as a likely cause and indicates
that the molecular autopsy must have two arms: genomics and
proteomics.
GENOMEWIDE ASSOCIATION STUDIES IN INFANT DEATH
In GWAS, up to 500,000 common polymorphisms are assessed
in a large cohort of individuals with a specific disease and this is
compared with a large cohort of controls from the general popula-
tion (18–32). Common polymorphisms are those that are present
in over 1% of the population. These are neutral changes that have
been in the population, without effective selection, for many thou-
sands of generations. Most of the polymorphisms occur in the
non-coding regions of the genome but they will be linked to reg-
ulatory elements and conserved functioning essential genes. The
impetus for these studies was the concept that common mutations
cause common disease and the expectation was that there would
be strong association between a small number of polymorphisms
and the disease under investigation. This has not been borne out
in practice. In schizophrenia, manic-depressive psychosis, multi-
ple sclerosis, hypertension, and type 2 diabetes mellitus a large
number of polymorphisms are found to be weakly associated
with the disease (18–32). The high heritability of schizophrenia
and manic-depressive psychosis, for example, is not explained
by neutral polymorphisms (28, 29). These results should have
been anticipated, because neutral mutations are neutral in evo-
lutionary terms and are not the main genetic cause of disease.
Disease is a consequence of deleterious mutations, against which
selection operates.
In the GWAS undertaken so far, most of the associations
between a polymorphism and a disease have odds ratios<1.5. The
significance level used in these studies is set at 0.05 for each poly-
morphism but since these assays test many hundreds of SNPs there
needs to be a correction for multiple testing such that the reporting
of false positives (or negatives) is minimized. In view of this large
cohorts are required to establish statistical significance and posi-
tive associations should be independently checked in a replication
set. However, if the odds ratio is raised then this does give a clue
to causation. Because it indicates that a linked gene influences the
risk of disease. This is particularly relevant if the linked genes have
a role in infection or inflammation. Neutral mutations are not the
main cause of disease but they can influence the risk of disease
by small margins. A neutral mutation can be disadvantageous in
relation to one organism but with a compensatory advantage in
relation to another; neutral overall in evolutionary terms.
In general, in epidemiological studies, association does not
equal causation. But there is an interesting argument that in GWAS
association does equal causation. This is because in meiosis there
is perfect randomization of neutral polymorphisms and this elim-
inates confounding factors. The perfect randomized trial. Not
everybody agrees with this idea, particularly since it depends on
there being no bias in the selection of the control population.
However, it does appear that associations, once established, give
clues to causation.
I am aware of one GWAS of a cohort of German SIDS cases.
This study was funded by the Foundation for the Study of Infant
Death (FSID), which has now been renamed the Lullaby Trust. The
results have been presented at a number of international meetings
but not yet published in full. This study found a number of poten-
tial associations with odds ratios between 1 and 1.5. One of the
associations reached statistical significance; the odds ratio was 1.5
and the upper bound of the 95% confidence interval was <2. The
research workers concerned are planning to enlarge the cohort
prior to publication. There are no details at present about the
specific loci (33).
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Genome wide association studies can also provide informa-
tion on copy number variants in the experimental and control
populations. The larger copy number variants are more likely
to indicate deleterious mutations and this can provide useful
additional information (34).
There have been a number of studies of cytokine regulatory
genes in SIDS (35–40), which are reviewed in detail in an accompa-
nying article (see Ferrante and Opdal) These studies are necessarily
smaller than GWAS and do not have the large control cohorts for
comparison. There is, however, some evidence that the balance of
pro- and anti-inflammatory cytokine responses can influence the
response to infection in general and influence the risk of SIDS.
Interaction between smoking and the cytokine response is a par-
ticular interesting area of investigation. Time will tell whether or
not GWAS confirms that cytokine regulatory genes have a role
in SIDS.
GENOME SEQUENCING IN INFANT DEATH
It is now possible to sequence the genome at a cost, which
is comparable to that of the standard infant autopsy. Whole
genome screening or whole exome screening can be undertaken
for around $2000 and the price is still falling. This is the inves-
tigation, which will reveal the extent to which genetic factors
predispose to infant death. The interpretation of the findings,
however, will still be extremely difficult, at least initially. Rec-
ognizing the small number of deleterious mutations in highly
conserved essential genes and distinguishing these from the vast
number of other changes in the genome will not be easy, but it is
a tractable problem.
In SUDI, the following findings are anticipated:
1. In some cases, a single deleterious mutation in an essential
gene will be, in itself, a sufficient explanation for death. We
already know that mutations in cardiac channelopathy genes
are responsible for approximately 10% of SUDI cases (41). This
information has come from sequencing only seven genes. If the
entire genome is sequenced it is inevitable that further exam-
ples will be found. Some of the mutations will arise de novo
and some will be present in the germ line of parents. Even in
these cases, synergistic interaction with other deleterious muta-
tions might be important and there will be some environmental
trigger, such as infection. Recognizing these single deleterious
mutations and working out,which are de novo will be important
for genetic counseling of the families.
2. Single deleterious mutations on X might be a major risk fac-
tor for SUDI in males. The male excess in SUDI could be due
to sex linked recessives or to a loss of heterozygous advantage
as argued above. Sequencing the X chromosome in males is
likely to yield a considerable amount of information relevant
to infant death.
3. Discerning the role of synergistic interaction of heterozygous
deleterious mutations in complex genetic systems will be much
more problematical. But it should be possible to determine the
actual genetic load of deleterious mutations and relate this to
risk of death. Infants with the most deleterious mutations will
be at increased risk of death of all types, including SUDI.
POPULATION MONITORING
The genomic load of deleterious mutations is a major factor in
health and disease. These mutations contribute to death in infancy
and in childhood. This is an inevitable conclusion of the observa-
tion that there is strong selection against these mutations. Selection
means genetic death caused by disease to which the mutations
predispose.
The rate at which new deleterious mutations enter the genome
is a random variable, and many factors will influence the rate.
Parental age, smoking, diet, and infection are likely to be involved
as is environmental pollution. The models used in this paper
indicate that if N falls then M will also fall over several genera-
tions and the population will become healthier. The rate of infant
death will fall. There is a public health imperative to measure and
monitor the rate at which new deleterious mutations enter the
genome so as to recognize causative factors and avoid them as far
as possible.
The considerable fall in the rate of infant mortality and overall
improvement in health over the last half century will be due to
many factors; but it is highly likely that part of this change is a
consequence of a fall in rates of somatic mutation in stem cells,
including germ cells. Improved social and economic conditions
could bring about this change in a number of ways including better
diet, less pollution, and less infection. We cannot, however, assume
that this process will continue its beneficial course. Economic
progress can lead to more pollution not less, and climate change
could have many detrimental effects.
DISCUSSION
In probing the pathogenesis of disease, I follow a simple but pow-
erful maxim: germs cause disease, genes act in complex networks
to prevent disease. In so far, as this idea is correct, and it will only be
correct in part, we can anticipate that common disease will be due
to common organisms. Our attention should therefore focus on
bacteria of the normal microbial flora and how they could interact
with a genome impaired by deleterious mutations (42, 43).
Whole genome sequencing and whole exome sequencing are
new techniques, which were not available in the twentieth century.
These techniques should allow us to define precisely the contri-
bution of genetic mutation to infant death. But interpretation of
the results of the analysis will not be easy and it will be some time
before we are confident in recognizing the significant changes. The
cost of genome sequencing is not inconsiderable, but it is compara-
ble with the total current cost of an autopsy. In cases were the cause
of infant death is a matter of legal dispute and criminal charges
are considered genome sequencing could lead to considerable cost
saving (6).
Disease is an interaction between environmental stress and
impaired genetic systems. Thus, genome sequencing will not pro-
vide a complete answer. It should be supplemented with the
other arm of the molecular autopsy, which is proteomic analy-
sis of body fluids. In particular, we need to seek and identify
bacterial secretory products in body fluids in order to diagnose
infection (5). This article, however, concentrates on the genetic
aspects because the genetic techniques are now ready for direct
application; the proteomic techniques are still in the phase of
development.
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A common counter-argument to the ideas presented in this
article is that nothing can be done about our genetic constitution
and sequencing the genome will not lead to any preventive strate-
gies. In my view, this is a misconception. Deleterious mutations
are ultimately caused by environmental factors and if we can iden-
tify the factors then the rate of mutation can be decreased. Indeed,
falling rates of somatic and germ line mutation are probably a
major factor in the improvement in health we have seen over the
last 50 years in the technologically advanced countries. Smoking
is mutagenic and if we could measure this directly it would be a
powerful incentive for young parents, contemplating a family, to
quit the habit.
In my experience, the question that parents want answering is
“why did my infant die?”; and this takes precedence in their mind
over discussions related to preventive strategies. The job of the
pathologists is to answer that question. We were unable to do so in
many cases in the twentieth century because the techniques of the
molecular autopsy were not available. Genome sequencing is now
available and should be used. Proteomic techniques will follow in
the near future.
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APPENDIX
The calculations are based on the assumption that the excess male death in SUDI is
entirely due to heterozygous deleterious mutations on X.
Consider the case in which 25% of males have a deleterious mutation on X.
In 100 cases of SUDI, there will be 60 males and 40 females.
The 20 excess males all have a deleterious mutation on X.
About 25% of the remaining 40 males also have a deleterious mutation on X.
Thus, 30 of 60 males (50%) have a deleterious mutation on X.
About 25% of the male population produces 50% of the deaths.
About 75% of the population produces the other 50% of the deaths.
Relative risk is (50÷ 25)÷ (50÷ 75)= 3.
Now consider the case in which 10% of males have a deleterious mutation on X.
In 100 cases of SUDI, there will be 60 males and 40 females.
The 20 excess males all have a deleterious mutation on X.
Just 10% of the remaining 40 males have a deleterious mutation on X.
Thus, 24 of 60 males (40%) have a deleterious mutation on X.
About 10% of the male population produces 40% of the male deaths.
The remaining 90% of the male population produces 60% of the male deaths.
Relative risk is (40÷ 10)÷ (60÷ 90)= 6.
Finally, consider the case in which 5% of the males have a deleterious mutation on X.
Twenty-two males of 60 (37%) SUDI deaths will have a deleterious mutation on X.
Thus, 5% of the population of males produces 37% of the deaths.
The remaining 95% of the population produces 63% of the deaths.
Relative risk is (37÷ 5)÷ (63÷ 95)= 11.
Please note that the relative risk for specific deleterious mutations will vary markedly.
The calculations relate to the mean of the distribution. The mean is likely to be a
constant regardless of time, population and race; hence the remarkable constancy
of Mage’s ratio – three male deaths for every two female deaths (15).
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